Davita’s Cendialcon Deal Puts Dialysis Payment Cycles Under the Microscope
Ecuador's Superintendence of Economic Competition authorized Davita's acquisition of 100% of the shares of Centro de Diálisis Contigo Cendialcon Cía. Ltda. The transaction was reviewed in the private-complementary hemodialysis markets of Latacunga and Ambato.
The regulator concluded that the purchase did not change the structure of those markets or create immediate horizontal anticompetitive risks. The same decision sits alongside a broader national expansion signal: Davita's group already has a network of 29 establishments in Ecuador.
Demand is structurally large
Around 20,000 people in Ecuador need dialysis or hemodialysis to survive. The state has covered the treatment since 2008 because it is classified as a catastrophic illness, but the public system lacks enough capacity and refers 88%, or about 17,000 patients, to private clinics.
The reported treatment cadence is three sessions of four hours per week per patient. That makes provider reliability and reimbursement timing material operating variables, not side issues.
The receivables signal
Cendialcon closed 2025 with 261 patients, up 11.5% from the previous year. Its accounts receivable reached USD 5.71 million, 27.13% above 2024, and its average collection time reached 486 days. Primicias attributes the balance primarily to pending payments from the Ministry of Public Health and IESS.
For an operator, that profile combines demand growth with working-capital pressure. For a buyer, the transaction is therefore about more than clinic count: it also brings exposure to payer concentration, public payment cycles, and the ability to finance ongoing treatment.
What to watch
The competition approval does not disclose a purchase price or a post-close operating plan. The key indicators are whether consolidation changes network capacity, how public reimbursements move through the system, and whether collection times improve.
The transaction is a healthcare-market event with financial infrastructure attached. The competitive finding is limited to the reviewed markets; the payment-cycle figures show why the sector still deserves close operating and credit attention.
Source: Primicias
Source
Primicias — "Davita compra el 100% de Cendialcon, empresa de hemodiálisis en Ecuador"
View originalSupport daily Ecuador business intelligence.
Research support funds source monitoring, data checks, editing, publishing, and sector coverage for professionals tracking Ecuador.